{"id":765787,"date":"2023-06-23T16:33:21","date_gmt":"2023-06-23T20:33:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/"},"modified":"2023-06-23T16:33:21","modified_gmt":"2023-06-23T20:33:21","slug":"ac-immune-holds-annual-general-meeting-of-shareholders-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/","title":{"rendered":"AC Immune Holds Annual General Meeting of Shareholders"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>AC Immune Holds Annual General Meeting of Shareholders<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left\">Shareholders approved all resolutions as proposed by the Board of Directors\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Lausanne, Switzerland, June 23, 2023<\/strong> \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes in person at the Annual General Meeting or through the Independent Proxy appointed by the shareholders.<\/p>\n<p align=\"justify\">Shareholders re-elected Douglas Williams, Monika B\u00fctler, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Shaw and Roy Twyman to their positions on the Board of Directors. Alan Colowick and Tom Graney did not stand for re-election and we thank them for their contributions. Douglas Williams will continue to serve as Chair of the Board.<\/p>\n<p align=\"justify\">\n        <strong>Douglas Williams, Chair of the Board of Directors of AC Immune, commented<\/strong>: \u201cIn 2022, AC Immune continued to deliver exciting developments in its broad and diverse pipeline of innovative product candidates, from the first ever live images of alpha-synuclein in patients\u2019 brains to the initiation of the ABATE Phase 1b\/2 clinical trial of ACI-24.060 in Alzheimer\u2019s disease (AD) and AD in Down syndrome, and the selection of ACI-35.030 for continued development in AD. In the coming period we will be reporting further progress with key amyloid-PET data from the ABATE trial of ACI-24.060 expected in the first half of 2024. With our unwavering focus on rigorous science and with the strength of our teams, Company management is driving towards bringing Precision Medicine to the treatment and prevention of neurodegenerative diseases.\u201d<\/p>\n<p align=\"justify\">Since the beginning of 2023, AC Immune reported:<\/p>\n<ul type=\"square\">\n<li style=\"text-align:justify\">Initial safety and immunogenicity results from the ABATE Phase 1b\/2 clinical trial of ACI-24.060 in AD, enabling the expansion of the trial into higher dose cohorts in AD and the opening of the study into the Down syndrome population<\/li>\n<li style=\"text-align:justify\">The initiation by our partner, Life Molecular Imaging, of the Phase 3 clinical trial, ADvance, assessing the Tau-PET tracer, PI-2620 in AD<\/li>\n<li style=\"text-align:justify\">Additional grant funding from the Michael J. Fox Foundation and Target ALS Foundation for research programs targeting TDP-43.\n<\/li>\n<\/ul>\n<p align=\"justify\">During the Annual General Meeting, shareholders also approved all other resolutions as proposed by the Board of Directors.<\/p>\n<p align=\"justify\">\n        <strong>About AC Immune SA <\/strong><br \/>\n        <br \/>AC Immune SA\u00a0is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen<sup>\u00ae<\/sup>\u00a0and Morphomer<sup>\u00ae<\/sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3.\u00a0AC Immune\u00a0has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including\u00a0Genentech, a member of the Roche Group, Eli Lilly and Company, and\u00a0others, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$3\u00a0billion\u00a0in potential milestone payments.<\/p>\n<p align=\"justify\">SupraAntigen<sup>\u00ae<\/sup>\u00a0is a registered trademark of\u00a0AC Immune SA\u00a0in the following territories: AU, EU, CH, GB, JP, RU, SG and\u00a0USA. Morphomer<sup>\u00ae<\/sup>\u00a0is a registered trademark of\u00a0AC Immune SA\u00a0in CN, CH, GB, JP, KR, NO and RU.<\/p>\n<p align=\"justify\">The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:450pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:281.4px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Head of <\/strong><br \/>\n            <strong>Investor Relations<\/strong><br \/>\n            <strong> &amp; Corporate Communications<\/strong><br \/>\n            <br \/>Gary Waanders, Ph.D., MBA<br \/>AC Immune<br \/>Phone: +41 21 345 91 91<br \/>Email: <a href=\"mailto:gary.waanders@acimmune.com\" rel=\"nofollow noopener\" target=\"_blank\">gary.waanders@acimmune.com<\/a><\/p>\n<\/td>\n<td style=\"width:318.6px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>U.S. Investors<\/strong><br \/>\n            <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>Phone: +1 212 915 2577 <br \/>Email: <a href=\"mailto:cdavis@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:281.4px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>International Media<\/strong><br \/>\n            <br \/>Chris Maggos<br \/>Cohesion Bureau<br \/>Phone: +41 79 367 6254<br \/>Email: <a href=\"mailto:chris.maggos@cohesionbureau.com\" rel=\"nofollow noopener\" target=\"_blank\">chris.maggos@cohesionbureau.com<\/a><\/p>\n<\/td>\n<td style=\"width:318.6px;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Forward looking statements<\/strong><br \/>\n        <br \/>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the\u00a0Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and\u00a0AC Immune\u00a0does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p \/>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/29f4055f-1475-458d-8c29-b97b844b1d60\" rel=\"noopener\">20230623_ACIU_AGM_FINAL<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZDlkOGE5NTAtZTQ1NC00ZGM0LTg0YjAtZjExY2M5N2U0YzY5LTEwMzc0NDM=\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes in person at the Annual General Meeting or through the Independent Proxy appointed by the shareholders. Shareholders re-elected Douglas Williams, Monika B\u00fctler, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Shaw and Roy Twyman to their positions on the Board of Directors. Alan Colowick and Tom Graney did not stand for re-election and we thank them for their contributions. Douglas Williams will continue to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune Holds Annual General Meeting of Shareholders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765787","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune Holds Annual General Meeting of Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune Holds Annual General Meeting of Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes in person at the Annual General Meeting or through the Independent Proxy appointed by the shareholders. Shareholders re-elected Douglas Williams, Monika B\u00fctler, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Shaw and Roy Twyman to their positions on the Board of Directors. Alan Colowick and Tom Graney did not stand for re-election and we thank them for their contributions. Douglas Williams will continue to &hellip; Continue reading &quot;AC Immune Holds Annual General Meeting of Shareholders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-23T20:33:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune Holds Annual General Meeting of Shareholders\",\"datePublished\":\"2023-06-23T20:33:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/\"},\"wordCount\":852,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/\",\"name\":\"AC Immune Holds Annual General Meeting of Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==\",\"datePublished\":\"2023-06-23T20:33:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-holds-annual-general-meeting-of-shareholders-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune Holds Annual General Meeting of Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune Holds Annual General Meeting of Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune Holds Annual General Meeting of Shareholders - Market Newsdesk","og_description":"AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes in person at the Annual General Meeting or through the Independent Proxy appointed by the shareholders. Shareholders re-elected Douglas Williams, Monika B\u00fctler, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Shaw and Roy Twyman to their positions on the Board of Directors. Alan Colowick and Tom Graney did not stand for re-election and we thank them for their contributions. Douglas Williams will continue to &hellip; Continue reading \"AC Immune Holds Annual General Meeting of Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-23T20:33:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune Holds Annual General Meeting of Shareholders","datePublished":"2023-06-23T20:33:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/"},"wordCount":852,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/","name":"AC Immune Holds Annual General Meeting of Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==","datePublished":"2023-06-23T20:33:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyNjc2MyM0MDE1NzIyNTIjMjAyNTg3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-holds-annual-general-meeting-of-shareholders-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune Holds Annual General Meeting of Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765787"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765787\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}